DOCSLIB.ORG

Guide to Antimicrobial Chemotherapy (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guide to Antimicrobial Chemotherapy (PDF) Antibiotic Stewardship Program Guide to Antimicrobial Chemotherapy 2020–2021, Tenth edition © 2020 UPMC All rights reserved. Contributors ................................................................................................. V Beta-lactam allergy documents UPMC Formulary Medications................................................................. VI Questionnaire .............................................................................................33 Antibiograms Documentation ...........................................................................................34 Housewide Evaluation and management pathway ...................................................35 UPMC Presbyterian ........................................................................... 2-12 Penicillin allergy background ..................................................................32 UPMC Shadyside ............................................................................. 13-16 Antibiotic Recommendations in Pulmonary Disease Organism/Site Specific - UPMC Presbyterian Mendelson’s syndrome .............................................................................37 Streptococcus pneumoniae ................................................................2,3 COPD Exacerbation ...................................................................................37 ICU antibiograms ............................................................................... 8-12 Aspiration Pneumonia Candida Species ......................................................................................7 Hospitalized < 5 days .............................................................................37 UPMC Hospitals Other Than UPMC Presbyterian-Shadyside ...........17 Hospitalized ≥ 5 days ............................................................................37 Organism Identification ......................................................................18, 19 Community Acquired Pneumonia Antibiotics by Class and Restriction................................................20, 21 On floor or In ICU Without Risks for Pseudomonas .........................38 Procedure for AMP Restricted Agents (Presbyterian Campus) ........22 In ICU or floor With Risks for Pseudomonas .....................................38 Procedure for AMP Restricted Agents(Shadyside Campus) .............23 Hospital-Acquired Pneumonia.................................................................39 Ventilator-Associated Pneumonia ..........................................................39 Anti-infective Agents That Should Not Be Crushed ...........................24 Pneumocystis Pneumonia (PJP) Vancomcyin Appropriate Use .................................................................25 Antimicrobial Therapy for .....................................................................40 Community-Associated MRSA (CA-MRSA) ....................................26, 27 Adjunctive Steroid Therapy for ...........................................................40 Microbiology and Dose Optimization Pearls .......................................28 Antibiotic Recommendations in Gastrointestinal Infections Antibiotic and Ethanol Lock Therapy.....................................................29 Antibiotic Prophylaxis Antibiotics of Choice by Organism For Spontaneous Bacterial Peritonitis ...............................................41 After Large GI bleed ..............................................................................41 Staphylococcus aureus Active SBP ..................................................................................................41 Methicillin-Sensitive .............................................................................30 Mild to Moderate Severity Community-Associated IAI ......................41 Methicillin-Resistant .............................................................................30 High Risk Severity or Health-Care Associated IAI ...............................42 Group A Streptococci (S pyogenes) .......................................................30 Crohn’s Disease Flare ................................................................................42 Listeria monocytogenes............................................................................30 C difficile Colitis ..........................................................................................42 Enterococcus spp ......................................................................................30 Stenotrophomonas malthophilia .............................................................30 Extended Spectrum Beta-Lactamase (ESBL) Producing Bacteria ...............................................................................30 Pseudomonas aeruginosa ........................................................................30 Duration of Antibiotic Treatment for Bloodstream Infections...........31 I II Antibiotic Recommendations in Skin/Soft Tissue Infections (SSTI) Empiric Treatment Guidelines for Candidiasis Infection severity .......................................................................................43 Candidemia .................................................................................................58 Purulent and Non-purulent SSTI .............................................................44 Candidiasis Necrotizing Soft Tissue Infections (NSTI)..............................................45 Intra-Abdominal .....................................................................................58 Wound Infection Endocarditis ............................................................................................58 Nontraumatic ..........................................................................................45 Endophthalmitis ......................................................................................59 Traumatic and Severe ...........................................................................45 Meningitis ...............................................................................................59 Mediastinitis ...............................................................................................46 Mucocutaneous .....................................................................................59 Diabetic Foot ...............................................................................................46 Esophageal .............................................................................................60 Bite Wounds Urinary .....................................................................................................60 Cat/Dog ....................................................................................................47 Vaginal .....................................................................................................60 Human ......................................................................................................47 Antifungal Recommendations in Systemic Fungal Infections Antibiotic Recommendations in Meningitis Bronchopulmonary Aspergillosis ............................................................61 Meningitis....................................................................................................48 Aspergilloma ...............................................................................................61 Head Trauma Invasive Aspergillosis ...............................................................................61 Basilar Skull Fracture ............................................................................48 Blastomycosis Pulmonary Infection and Penetrating Trauma ...............................................................................49 Extra-CNS Disease .........................................................................61, 62 Post Neurosurgical or CSF Shunt .......................................................49 CNS Disease ...........................................................................................62 Antibiotic Recommendations in Endocarditis (Native and Prosthetic Coccidiomycosis Pulmonary and Extra-CNS Disease .........................62 Valve) CNS Disease ...........................................................................................63 Streptococci .........................................................................................50, 51 Cryptococcosis Pulmonary Disease .......................................................63 Enterococci ...........................................................................................51, 52 Cryptococcosis (Meningoencephalitis) .................................................64 Staphylococcus aureus Histoplasmosis Pulmonary and Disseminated ......................................65 Methicillin-Susceptible .........................................................................53 Mucormycosis ............................................................................................65 Methicillin-Resistant .............................................................................54 Sporotrichosis Cutaneous ........................................................................65 HACEK Organisms......................................................................................54 Deep-Seated (mild/moderate) .............................................................66 Gram-Negative ...........................................................................................54 Disseminated/Meningeal/Severe Deep-Seated
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Activity of Aztreonam in Combination with Ceftazidime-Avibactam Against
    Diagnostic Microbiology and Infectious Disease 99 (2021) 115227 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing ☆ ☆☆ ★ Pseudomonas aeruginosa , , Michelle Lee a, Taylor Abbey a, Mark Biagi b, Eric Wenzler a,⁎ a College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA b College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA article info abstract Article history: Existing data support the combination of aztreonam and ceftazidime–avibactam against serine-β-lactamase Received 29 June 2020 (SBL)– and metallo-β-lactamase (MBL)–producing Enterobacterales, although there is a paucity of data against Received in revised form 15 September 2020 SBL- and MBL-producing Pseudomonas aeruginosa. In this study, 5 SBL- and MBL-producing P. aeruginosa (1 Accepted 19 September 2020 IMP, 4 VIM) were evaluated against aztreonam and ceftazidime–avibactam alone and in combination via broth Available online xxxx microdilution and time-kill analyses. All 5 isolates were nonsusceptible to aztreonam, aztreonam–avibactam, – – Keywords: and ceftazidime avibactam. Combining aztreonam with ceftazidime avibactam at subinhibitory concentrations Metallo-β-lactamase produced synergy and restored bactericidal activity in 4/5 (80%) isolates tested. These results suggest that the VIM combination of aztreonam and ceftazidime–avibactam may be a viable treatment option against SBL- and IMP MBL-producing P. aeruginosa. Aztreonam © 2020 Elsevier Inc. All rights reserved. Ceftazidime–avibactam Synergy 1. Introduction of SBLs and MBLs harbored by P. aeruginosa are fundamentally different than those in Enterobacterales (Alm et al., 2015; Kazmierczak et al., The rapid global dissemination of Ambler class B metallo-β- 2016; Periasamy et al., 2020; Poirel et al., 2000; Watanabe et al., lactamase (MBL) enzymes along with their increasing diversity across 1991).
    [Show full text]
  • Chapter 12 Antimicrobial Therapy Antibiotics
    Chapter 12 Antimicrobial Therapy Topics: • Ideal drug - Antimicrobial Therapy - Selective Toxicity • Terminology - Survey of Antimicrobial Drug • Antibiotics - Microbial Drug Resistance - Drug and Host Interaction An ideal antimicrobic: Chemotherapy is the use of any chemical - soluble in body fluids, agent in the treatment of disease. - selectively toxic , - nonallergenic, A chemotherapeutic agent or drug is any - reasonable half life (maintained at a chemical agent used in medical practice. constant therapeutic concentration) An antibiotic agent is usually considered to - unlikely to elicit resistance, be a chemical substance made by a - has a long shelf life, microorganism that can inhibit the growth or - reasonably priced. kill microorganisms. There is no ideal antimicrobic An antimicrobic or antimicrobial agent is Selective Toxicity - Drugs that specifically target a chemical substance similar to an microbial processes, and not the human host’s. antibiotic, but may be synthetic. Antibiotics Spectrum of antibiotics and targets • Naturally occurring antimicrobials – Metabolic products of bacteria and fungi – Reduce competition for nutrients and space • Bacteria – Streptomyces, Bacillus, • Molds – Penicillium, Cephalosporium * * 1 The mechanism of action for different 5 General Mechanisms of Action for antimicrobial drug targets in bacterial cells Antibiotics - Inhibition of Cell Wall Synthesis - Disruption of Cell Membrane Function - Inhibition of Protein Synthesis - Inhibition of Nucleic Acid Synthesis - Anti-metabolic activity Antibiotics
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • FDA Drug Safety Communication: FDA Cautions About Dose Confusion and Medication Error with Antibacterial Drug Avycaz (Ceftazidime and Avibactam)
    FDA Drug Safety Communication: FDA cautions about dose confusion and medication error with antibacterial drug Avycaz (ceftazidime and avibactam) Safety Announcement [09-22-2015] The U.S. Food and Drug Administration (FDA) is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and avibactam) due to confusion about the drug strength displayed on the vial and carton labels. Avycaz was initially approved with the vial and carton labels displaying the individual strengths of the two active ingredients (i.e., 2 gram/0.5 gram); however, the product is dosed based on the sum of the active ingredients (i.e., 2.5 gram). To prevent medication errors, we have revised the labels to indicate that each vial contains Avycaz 2.5 gram, equivalent to ceftazidime 2 gram and avibactam 0.5 gram (see Photos). Avycaz is approved for intravenous administration to treat complicated infections in the urinary tract, or in combination with the antibacterial drug metronidazole to treat complicated infections in the abdomen in patients with limited or no alternative treatment options. Antibacterial drugs work by killing or stopping the growth of bacteria that can cause illness. Since Avycaz’s approval in February 2015, we have received reports of three medication error cases related to confusion on how the strength was displayed on the Avycaz vial and carton labels. Two cases stated that the errors occurred during preparation of the dose in the pharmacy. The third case described concern about the potential for confusion because the strength displayed for Avycaz differs from how the strength is displayed for other beta-lactam/beta-lactamase antibacterial drugs.
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Identification of Pasteurella Species and Morphologically Similar Organisms
    UK Standards for Microbiology Investigations Identification of Pasteurella species and Morphologically Similar Organisms Issued by the Standards Unit, Microbiology Services, PHE Bacteriology – Identification | ID 13 | Issue no: 3 | Issue date: 04.02.15 | Page: 1 of 28 © Crown copyright 2015 Identification of Pasteurella species and Morphologically Similar Organisms Acknowledgments UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk- standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical- laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations- steering-committee). The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content. For further information please contact us at: Standards Unit Microbiology Services Public Health England 61 Colindale Avenue London NW9 5EQ E-mail: [email protected] Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality- and-consistency-in-clinical-laboratories UK Standards for Microbiology Investigations are produced in association with: Logos correct at time of publishing. Bacteriology – Identification | ID 13 | Issue no: 3 | Issue date: 04.02.15 | Page: 2 of 28 UK Standards for Microbiology Investigations | Issued by the Standards Unit, Public Health England Identification of Pasteurella species and Morphologically Similar Organisms Contents ACKNOWLEDGMENTS .........................................................................................................
    [Show full text]
  • Microbial Biofilms – Veronica Lazar and Eugenia Bezirtzoglou
    MEDICAL SCIENCES – Microbial Biofilms – Veronica Lazar and Eugenia Bezirtzoglou MICROBIAL BIOFILMS Veronica Lazar University of Bucharest, Faculty of Biology, Dept. of Microbiology, 060101 Aleea Portocalelor No. 1-3, Sector 6, Bucharest, Romania; Eugenia Bezirtzoglou Democritus University of Thrace - Faculty of Agricultural Development, Dept. of Microbiology, Orestiada, Greece Keywords: Microbial adherence to cellular/inert substrata, Biofilms, Intercellular communication, Quorum Sensing (QS) mechanism, Dental plaque, Tolerance to antimicrobials, Anti-biofilm strategies, Ecological and biotechnological significance of biofilms Contents 1. Introduction 2. Definition 3. Microbial Adherence 4. Development, Architecture of a Mature Biofilm and Properties 5. Intercellular Communication: Intra-, Interspecific and Interkingdom Signaling, By QS Mechanism and Implications 6. Medical Significance of Microbial Biofilms Formed on Cellular Substrata and Medical Devices 6.1. Microbial Biofilms on Medical Devices 6.2. Microorganisms - Biomaterial Interactions 6.3. Phenotypical Resistance or Tolerance to Antimicrobials; Mechanisms of Tolerance 7. New Strategies for Prevention and Treatment of Biofilm Associated Infections 8. Ecological Significance 9. Biotechnological / Industrial Applications 10. Conclusion Acknowledgments Glossary Bibliography Biographical Sketches UNESCO – EOLSS Summary A biofilm is a sessileSAMPLE microbial community coCHAPTERSmposed of cells embedded in a matrix of exopolysaccharide matrix attached to a substratum or interface. Biofilms
    [Show full text]
  • Phylogenomic Networks Reveal Limited Phylogenetic Range of Lateral Gene Transfer by Transduction
    The ISME Journal (2017) 11, 543–554 OPEN © 2017 International Society for Microbial Ecology All rights reserved 1751-7362/17 www.nature.com/ismej ORIGINAL ARTICLE Phylogenomic networks reveal limited phylogenetic range of lateral gene transfer by transduction Ovidiu Popa1, Giddy Landan and Tal Dagan Institute of General Microbiology, Christian-Albrechts University of Kiel, Kiel, Germany Bacteriophages are recognized DNA vectors and transduction is considered as a common mechanism of lateral gene transfer (LGT) during microbial evolution. Anecdotal events of phage- mediated gene transfer were studied extensively, however, a coherent evolutionary viewpoint of LGT by transduction, its extent and characteristics, is still lacking. Here we report a large-scale evolutionary reconstruction of transduction events in 3982 genomes. We inferred 17 158 recent transduction events linking donors, phages and recipients into a phylogenomic transduction network view. We find that LGT by transduction is mostly restricted to closely related donors and recipients. Furthermore, a substantial number of the transduction events (9%) are best described as gene duplications that are mediated by mobile DNA vectors. We propose to distinguish this type of paralogy by the term autology. A comparison of donor and recipient genomes revealed that genome similarity is a superior predictor of species connectivity in the network in comparison to common habitat. This indicates that genetic similarity, rather than ecological opportunity, is a driver of successful transduction during microbial evolution. A striking difference in the connectivity pattern of donors and recipients shows that while lysogenic interactions are highly species-specific, the host range for lytic phage infections can be much wider, serving to connect dense clusters of closely related species.
    [Show full text]
  • Role of Anaerobes in Dental Infection-A Review
    H.Sharanya et al /J. Pharm. Sci. & Res. Vol. 10(3), 2018, 547-548 Role of Anaerobes in Dental Infection-A Review H.Sharanya, Dr.Gopinath Saveetha Dental College And Hospitals Abstract: Aim:To make a review on role of anaerobes in dental infection. Objective:To secure knowledge about the role played by anaerobes in dental infections. Background :Anaerobic bacteria have been shown to play a role in infection of all types in humans.Anaerobes make up a significant part of the oral and dental indigenous and pathogenic flora. Common anaerobic isolates include Fusobacterium, Bacteroides, Actinomyces, Peptococcus, Peptostreptococcus, Selenomonas, Eubacterium, Propionibacterium, and Treponema.Their role in periodontal disease, root canal infections, infections of the hard and soft oral tissue, as well as their importance as foci for disseminated infectious disease is well established. Reason:To enumerate the part played by anaerobes in dental infection and to know how they are interacting towards the infection and to make the people aware of those anaerobes and causes in dental infection. INTRODUCTION : variety of microorganisms(12).There are soft and hard structures, Infections caused by anaerobic bacteria are common, and may be and certain,- areas show differences in oxygen tension and in serious and life-threatening. Anaerobes predominant in the nutrition. Some surfaces protect the organisms from friction and bacterial flora of normal human skin and mucous membranes, and the flow of oral secretions, whereas other surfaces do not . are a common cause of bacterial infections of endogenous origin. Infections due to anaerobes can evolve all body systems and ANAEROBIC INFECTIONS OF THE ORAL CAVITY sites(1).The predominate ones include: abdominal, pelvic, It may be appropriate to discuss these infections according to their respiratory, and skin and soft tissues infections.
    [Show full text]
  • Yopb and Yopd Constitute a Novel Class of Yersinia Yop Proteins
    INFECTION AND IMMUNITY, Jan. 1993, p. 71-80 Vol. 61, No. 1 0019-9567/93/010071-10$02.00/0 Copyright © 1993, American Society for Microbiology YopB and YopD Constitute a Novel Class of Yersinia Yop Proteins SEBASTIAN HAKANSSON,1 THOMAS BERGMAN,1 JEAN-CLAUDE VANOOTEGHEM, 2 GUY CORNELIS,2 AND HANS WOLF-WATZ1* Department of Cell and Molecular Biology, University of Umed, S-901 87 Umed, Sweden,' and Microbial Pathogenesis Unit, Intemnational Institute of Cellular and Molecular Pathology and Faculte6 de Medecine, Universite Catholique de Louvain, B-1200 Brussels, Belgium2 Received 21 May 1992/Accepted 21 October 1992 Virulent Yersinia species harbor a common plasmid that encodes essential virulence determinants (Yersinia outer proteins [Yops]), which are regulated by the extracellular stimuli Ca2" and temperature. The V-antigen-encoding operon has been shown to be involved in the Ca2 -regulated negative pathway. The genetic organization of the V-antigen operon and the sequence of the krGVH genes were recently presented. The V-antigen operon was shown to be a polycistronic operon having the gene order kcrGVH-yopBD (T. Bergman, S. Hakansson, A. Forsberg, L. Norlander, A. Maceliaro, A. Backman, I. Bolin, and H. Wolf-Watz, J. Bacteriol. 173:1607-1616, 1991; S. B. Price, K. Y. Leung, S. S. Barve, and S. C. Straley, J. Bacteriol. 171:5646-5653, 1989). We present here the sequence of the distal part of the V-antigen operons of Yersinia pseudotuberculosis and Yersinia enterocolitica. The sequence information encompasses theyopB andyopD genes and a downstream region in both species. We conclude that the V-antigen operon ends with theyopD gene.
    [Show full text]